Post- American Society of Hematology Annual Meeting (ASH) Survey 2007

Why Panel Intelligence?

Our Markets

Our Services

Specialties:

Newest Reports:

Post- American Society of Hematology Annual Meeting (ASH) Survey 2007

December 2007

Description: Survey with key findings.

Study Description:

Topic	Multiple Myeloma
Respondent Type	Physicians
Specialty	Oncology/Hematology
Region	United States only
Methodology	Online survey, self-administered via a Panel Intelligence website � Self-administered survey � Approximately 30 minutes duration � 54 total respondents � Fielded online from December 12, 2007 to December 18, 2007

Objectives:

To determine trends and practices in the treatment of multiple myeloma following data presentations at American Society of Hematology in 2007. Specifically to:

� Understand multiple myeloma treatment background.

� Analyze treatment trends for SCT and non-SCT multiple myeloma patients.

� Assess Revlimid and Velcade data presented at ASH 2007.

� Evaluate trends in other therapies discussed at ASH 2007.

Products Mentioned in This Report:

Company	Ticker Symbol	Product(s)
Celgene Corporation	CELG	Thalidomide & Revlimid (Lenalidomide)
Genzyme	GENZ	Mozobil
Millennium	MLNM	Bortezomib (Velcade)
Pharmion Corporation	PHRM	Vidaza
Genentech	DNA	Rituxan
Cephalon	CEPH	Treanda

Inclusion Criteria and Respondent Demographics:

Inclusion Criteria

� US-based board certified hematologists/oncologists

� Attended 2007 ASH in Atlanta (Dec 7-11)

� Attended frontline MM session

� Treating at least 10 MM patients per month

� 2 to 30 years of practice experience

� Spend 50%+ of professional time in clinical practice

Reports become free one year after the publication date.

about us

Specialties:

Most Popular Reports:

Newest Reports: